Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896414 | 0.86 | CNR2 (0.56) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4896793 | 0.81 | CNR2 (0.52) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12795913 | 0.81 | CNR2 (0.57) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5708618 | 0.81 | CNR2 (0.54) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4891654 | 0.81 | CNR2 (0.54) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4895114 | 0.78 | CNR2 (0.52) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4900417 | 0.78 | CNR2 (0.55) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL541936 | 0.78 | CNR2 (0.57) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4898354 | 0.78 | CNR2 (0.57) | CNR2SYKCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4898977 | 0.77 | CNR2 (0.65) | CNR2SYKCYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885SYK 2878/4885CYP2C9 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.